OncoMatch/Clinical Trials/NCT06574022
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
Is NCT06574022 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Bupivacain and Exparel for mastectomy; lymphedema.
Treatment: Bupivacain · Exparel — The purpose this research is to compare two different standards of care for pain management and two different standards of care for local numbing medicine for breast cancer patients who will have a total mastectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: BRCA1 pathogenic mutation
Allowed: BRCA2 pathogenic mutation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Cincinnati Medical Center · Cincinnati, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify